TCDA - Tricida expects top-line data from VALOR-CKD trial in Q4 due to conflict in Ukraine

Tricida (NASDAQ:TCDA) provided an update on the anticipated date for top-line data from the VALOR-CKD trial based on the ongoing events in Ukraine. ~15% of the patients randomized in VALOR-CKD are from Ukraine. Given the uncertainty around future participation of Ukrainian subjects in the trial and the potential challenges to collecting and monitoring data from Ukrainian sites, top-line data from the trial is now anticipated early in Q4 of 2022 vs. previous guidance of Q3. The revised guidance is based on TCDA's evaluation of the current situation in Ukraine, which is dynamic. Its estimates may change as events in Ukraine evolve. TCDA believes it will need this incremental time to deal with anticipated disruptions and/or delays in data collection. The company does not expect the utility of the data already collected from Ukrainian subjects to be affected. TCDA believes its financial resources will extend for ~6 months following the anticipated

For further details see:

Tricida expects top-line data from VALOR-CKD trial in Q4 due to conflict in Ukraine